Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Patent
1997-11-12
2000-09-12
Spivack, Phyllis G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
514114, 514400, 514438, 514561, 514562, 514565, A61K 31195, A61K 31381, A61K 31472, A61K 31662
Patent
active
061179086
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
The present invention relates to the use of GABA.sub.B receptor agonists for the inhibition of transient lower esophageal sphincter relaxations; for the treatment of gastro-esophageal reflux disease; and/or for the treatment of regurgitation in infants.
BACKGROUND ART
In some humans, the lower esophageal sphincter (LES) is prone to relaxing more frequently than in other humans. As a consequence, fluid from the stomach can pass into the esophagus since the mechanical barrier is temporarily lost at such times, an event hereinafter referred to as "reflux".
Gastro-esophageal reflux disease (GERD) is the most prevalent upper gastrointestinal tract disease. Current therapy has aimed at reducing gastric acid secretion, or by reducing esophageal acid exposure by enhancing esophageal clearance, lower esophageal sphincter tone and gastric emptying. The major mechanism behind reflux has been considered to depend on a hypotonic lower esophageal sphincter. However, recent research (e.g. Holloway & Dent (1990) Gastroenterol. Clin. N. Amer. 19, 517-535) has shown that most reflux episodes occur during transient lower esophageal sphincter relaxations (TLESR), i.e. relaxations not triggered by swallows. It has also been shown that gastric acid secretion usually is normal in patients with GERD.
Consequently, there is a need for compounds which reduce the incidence of TLESR and thereby prevent reflux. Ideally, the compound should have an effect duration of approximately 12 h. since most reflux occurs during daytime and postprandially.
A pharmaceutical composition comprising a local anaesthetic, adapted to inhibit relaxation of the lower esophageal sphincter, is disclosed in WO 87/04077 and in U.S. Pat. No. 5,036,057.
GABA (4-aminobutanoic acid) is an endogenous neurotransmitter in the central and peripheral nervous systems. Receptors for GABA have traditionally been divided into GABA.sub.A and GABA.sub.B receptor subtypes. GABA.sub.B receptors (for a review see Kerr, D. I. B. and Ong, J. (1995) Pharmac. Ther. vol. 67, pp.187-246) belong to the superfamily of G-protein coupled receptors. GABA.sub.B receptor agonists are described as being of use in the treatment of CNS disorders, such as muscle relaxation in spinal spasticity, cardiovascular disorders, asthma, gut motility disorders such as irritable bowel syndrome and as prokinetic and anti-tussive agents. GABA.sub.B receptor agonists have also been disclosed as useful in the treatment of emesis (WO 96/11680).
The GABA.sub.B receptor agonist baclofen (4-amino-3-(4-chlorophenyl)butanoic acid) (Swiss patent No. CH 449,046) has been the most studied of the GABA analogs. ##STR1##
Other GABA.sub.B receptor agonists or partial agonists are disclosed in: EP 0356128; EP 0181833; EP 0399949; EP 0463969; and FR 2,722,192. For a review on the chemistry of GABA.sub.B modulators, see Froestl, W. and Mickel, S. J. in: The GABA Receptors, pp.271-296 (Eds. S. J. Enna and N. G. Bowery, Humana Press Inc., Totowa, N.J., U.S.A. 1997)
It is known in the art that drug screening can be improved by using cells which are transfected with a cloned receptor gene. Such transfected cells may offer several advantages over traditional screening, the most important being presumably selectivity. Another advantage of transfected cells is that they allow assessment of the activity of drugs on cloned human receptors. The fact that the GABA.sub.B receptor has recently been cloned (Kaupmann et al., Nature 386(6622), 239-246, Mar. 20, 1997) thus offers the opportunity to develop more specific drugs acting on the GABA.sub.B receptor. The said article discloses two subtypes of the receptor from rat, designated GABA.sub.B R1a and GABA.sub.B R1b, but it was made very clear that several other subtypes could be isolated.
DISCLOSURE OF THE INVENTION
It has been found surprisingly that GABA.sub.B receptor agonists can be used for the inhibition of transient lower esophageal sphincter relaxations, and thus for the treatment of gastro-esophageal reflux disease.
Consequently, the present invention pro
REFERENCES:
patent: 5036057 (1991-07-01), Martin
patent: 5491134 (1996-02-01), Sher et al.
Washabau et. al., Brain Research Bulletin 38: 587-594 (1995).
Nakajima et. al., Neurochem. Res. 21: 211-215 (1996).
Andrews Paul L. R.
Lehmann Anders
Astra Aktiebolag
Spivack Phyllis G.
LandOfFree
Use of GABA.sub.B receptor agonists as reflux inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of GABA.sub.B receptor agonists as reflux inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of GABA.sub.B receptor agonists as reflux inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-96746